Document is current
Any future updates will be listed below
-
Authors
Guan, Changge https://orcid.org/0000-0003-2531-6821
Torres, Marcelo D. T. https://orcid.org/0000-0002-6165-9138
Li, Sufen
de la Fuente-Nunez, Cesar https://orcid.org/0000-0002-2005-5629
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM138201)
United States Department of Defense | Defense Threat Reduction Agency (HDTRA1-21-1-0014)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 13 May 2025
First Online: 12 July 2025
Competing interests
: Cesar de la Fuente-Nunez is a co-founder and scientific advisor to Peptaris, Inc., provides consulting services to Invaio Sciences and is a member of the Scientific Advisory Boards of Nowture S.L. Peptidus, European Biotech Venture Builder, the Peptide Drug Hunting Consortium (PDHC), ePhective Therapeutics, Inc., and Phare Bio. The de la Fuente Lab has received research funding or in-kind donations from United Therapeutics, Strata Manufacturing PJSC, and Procter & Gamble, none of which were used in support of this work. M.D.T.T. is a co-founder and scientific advisor to Peptaris, Inc. The remaining authors declare no competing interests. An invention disclosure associated with this work has been filed.
